|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Vinflunine
|
MedKoo Code#: 203150
|
|
Name: Vinflunine
|
|
CAS#: 162652-95-1
Synonym:
methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-[(4R,6R,8S)-
4-(1,1-difluoroethyl)- 8-(methoxycarbonyl)-
1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-b]indol-
8-yl]- 3-hydroxy- 16-methoxy- 1-methyl-
6,7-didehydroaspidospermidine- 3-carboxylate.
IUPAC/Chemical name:
(3aR,3a1R,4R,5S,5aR,10bR)-methyl
4-acetoxy-9-((2S,4S,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate
|
|
Chemical structure |
Theoretical analysis
|
|
|
Chemical Formula: C45H54F2N4O8
Exact Mass: 816.39097
Molecular Weight: 816.93
m/z: 816.39097 (100.0%), 817.39433 (48.7%),
818.39768 (11.6%), 819.40104 (1.8%), 818.39522 (1.6%), 817.38801
(1.5%)
Elemental Analysis: C, 66.16; H, 6.66; F,
4.65; N, 6.86; O, 15.67
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
vinflunine is a
bi-fluorinated derivative of the semi-synthetic vinca alkaloid
vinorelbine with antitubulin, antineoplastic, and antiangiogenic
activities. Vinflunine inhibits tubulin assembly without any
stablization of assembled microtubules at concentrations comparable to
those of other vinca alkaloids such as vincristine, vinblastine and
vinorelbine; this effect on microtubule dynamics results in cell cycle
arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this
agent binds weakly to the vinca-binding site, indicating that vinflunine
may exhibit reduced neurotoxicity. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
According to
http://en.wikipedia.org/wiki/Vinflunine; Vinflunine (INN, trade name
Javlor) is a novel fluorinated Vinca alkaloid undergoing research for
the treatment of bladder cancer. It was originally discovered by the
team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers
University), developed by Laboratoires Pierre Fabre and was licensed to
Bristol-Myers Squibb for development in certain countries, including the
United States. On November 23, 2007, Pierre Fabre and BMS announced that
they are terminating their license agreement for the development of
vinflunine.
Current developer:
Laboratoires Pierre Fabre; Bristol-Myers Squibb.
1: Monneret C. [Current impact of natural
products in the discovery of anticancer drugs]. Ann Pharm Fr. 2010
Jul;68(4):218-32. Epub 2010 Jun 19. French. PubMed PMID: 20637355.
2: Ng JS. Vinflunine: review of a new vinca alkaloid and its potential
role in oncology. J Oncol Pharm Pract. 2010 Jun 28. [Epub ahead of
print] PubMed PMID: 20584744.
3: Frampton JE, Moen MD. Vinflunine. Drugs. 2010 Jul 9;70(10):1283-93.
doi: 10.2165/11204970-000000000-00000. PubMed PMID: 20568834.
4: Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang
NJ. Second-line systemic therapy and emerging drugs for metastatic
transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010 May
25. [Epub ahead of print] PubMed PMID: 20537950.
5: Théodore C. [Treatment strategies for metastatic patients in bladder
cancer]. Bull Cancer. 2010;97 Suppl Cancer de la vessie:27-33. French.
PubMed PMID: 20534387.
6: Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA.
Phase II trial of vinflunine in relapsed small cell lung cancer. J
Thorac Oncol. 2010 Jun;5(6):874-8. PubMed PMID: 20521355.
7: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2010 Mar;32(2):133-47. PubMed PMID: 20401351.
8: Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A,
Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC. A phase I evaluation of the
combination of vinflunine and erlotinib in patients with refractory
solid tumors. Invest New Drugs. 2010 Apr 13. [Epub ahead of print]
PubMed PMID: 20387090.
9: Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel
J, Sun X, Bennouna J, Santoro A, Biesma B, Delgado FM, Salhi Y,
Vaissiere N, Hansen O, Tan EH, Quoix E, Garrido P, Douillard JY. Phase
III trial comparing vinflunine with docetaxel in second-line advanced
non-small-cell lung cancer previously treated with platinum-containing
chemotherapy. J Clin Oncol. 2010 May 1;28(13):2167-73. Epub 2010 Mar 29.
PubMed PMID: 20351334.
10: Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E,
Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors
in patients with advanced transitional cell carcinoma of the urothelial
tract experiencing treatment failure with platinum-containing regimens.
J Clin Oncol. 2010 Apr 10;28(11):1850-5. Epub 2010 Mar 15. PubMed PMID:
20231682.
11: Souquet PJ, Krzakowski M, Ramlau R, Sun XS, Lopez-Vivanco G, Puozzo
C, Pouget JC, Pinel MC, Rosell R. Phase I/II and pharmacokinetic study
of intravenous vinflunine in combination with cisplatin for the
treatment of chemonaive patients with advanced non-small-cell lung
cancer. Clin Lung Cancer. 2010 Mar 1;11(2):105-13. PubMed PMID:
20199976.
12: Sonpavde G, Rosenberg JE, Hahn NM, Galsky MD, Bangs R, Sternberg CN,
Vogelzang NJ. Suggestions for regulatory agency approval of second-line
systemic therapy for metastatic transitional cell carcinoma. J Clin
Oncol. 2010 May 1;28(13):e205-7; author reply e208. Epub 2010 Feb 16.
PubMed PMID: 20159797.
13: Hainsworth JD, Meluch AA, Lane CM, Spigel DR, Burris HA 3rd, Gandhi
JG, Crane EJ, Stipanov MA, Greco FA. Single agent vinflunine in the
salvage treatment of patients with castration-resistant prostate cancer:
a phase II trial of the Sarah Cannon research consortium. Cancer Invest.
2010 Mar;28(3):275-9. PubMed PMID: 20158340.
14: Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B,
Stinchcombe TE, Keller K, Dees EC. Phase I trial of vinflunine and
pemetrexed in refractory solid tumors. Invest New Drugs. 2009 Oct 15. [Epub
ahead of print] PubMed PMID: 19830387.
15: Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard
G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM,
Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H.
Phase III trial of vinflunine plus best supportive care compared with
best supportive care alone after a platinum-containing regimen in
patients with advanced transitional cell carcinoma of the urothelial
tract. J Clin Oncol. 2009 Sep 20;27(27):4454-61. Epub 2009 Aug 17.
Erratum in: J Clin Oncol. 2010 Jan 1;28(1):182. Winquist, Eric [added].
PubMed PMID: 19687335.
16: Murphy CG, Seidman AD. Evolving approaches to metastatic breast
cancer previously treated with anthracyclines and taxanes. Clin Breast
Cancer. 2009 Jun;9 Suppl 2:S58-65. Review. PubMed PMID: 19596644.
17: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2009 May;31(4):263-98. PubMed PMID: 19557204.
18: Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr
Opin Urol. 2009 Sep;19(5):533-9. Review. PubMed PMID: 19550334.
19: Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN,
Smith DC, Ringuette S, de Wit E, Pautret V, George C. Vinflunine in
platinum-pretreated patients with locally advanced or metastatic
urothelial carcinoma: results of a large phase 2 study. Cancer. 2009 Sep
15;115(18):4110-7. PubMed PMID: 19536904.
20: Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC,
Tubiana-Hulin M, Slabber CF, Caroff-Paraïso I, Alberts AS, Ayed FB.
Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of
Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based
Chemotherapy. Am J Clin Oncol. 2009 May 29. [Epub ahead of print] PubMed
PMID: 19487917.
21: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266.
22: Vaishampayan U. Systemic therapy of advanced urothelial cancer. Curr
Treat Options Oncol. 2009 Aug;10(3-4):256-66. Epub 2009 Apr 29. Review.
PubMed PMID: 19408129.
23: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798.
24: Bachner M, De Santis M. Vinflunine in the treatment of bladder
cancer. Ther Clin Risk Manag. 2008 Dec;4(6):1243-1253. PubMed PMID:
19337431; PubMed Central PMCID: PMC2643105.
25: Morris PG, Fornier MN. Novel anti-tubulin cytotoxic agents for
breast cancer. Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85. Review.
PubMed PMID: 19192956.
26: Gan PP, Kavallaris M. Tubulin-targeted drug action: functional
significance of class ii and class IVb beta-tubulin in vinca alkaloid
sensitivity. Cancer Res. 2008 Dec 1;68(23):9817-24. PubMed PMID:
19047161.
27: Tomillero A, Moral MA. Gateways to clinical trials. July-August
2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PubMed
PMID: 18850047.
28: Kindler HL. Systemic treatments for mesothelioma: standard and
novel. Curr Treat Options Oncol. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3.
Review. PubMed PMID: 18770046; PubMed Central PMCID: PMC2782121.
29: Jordan MA, Horwitz SB, Lobert S, Correia JJ. Exploring the
mechanisms of action of the novel microtubule inhibitor vinflunine.
Semin Oncol. 2008 Jun;35(3 Suppl 3):S6-S12. Review. PubMed PMID:
18538179.
30: Bellmunt J, Delgado FM, George C. Clinical activity of vinflunine in
transitional cell carcinoma of the urothelium and other solid tumors.
Semin Oncol. 2008 Jun;35(3 Suppl 3):S34-43. Review. PubMed PMID:
18538178.
31: Fahy J, Hellier P, Breillout F, Bailly C. Vinflunine: discovery and
synthesis of a novel microtubule inhibitor. Semin Oncol. 2008 Jun;35(3
Suppl 3):S3-5. Review. PubMed PMID: 18538177.
32: Lobert S, Puozzo C. Pharmacokinetics, metabolites, and preclinical
safety of vinflunine. Semin Oncol. 2008 Jun;35(3 Suppl 3):S28-33.
Review. PubMed PMID: 18538176.
33: Kavallaris M, Annereau JP, Barret JM. Potential mechanisms of
resistance to microtubule inhibitors. Semin Oncol. 2008 Jun;35(3 Suppl
3):S22-7. Review. PubMed PMID: 18538175.
34: Braguer D, Barret JM, McDaid H, Kruczynski A. Antitumor activity of
vinflunine: effector pathways and potential for synergies. Semin Oncol.
2008 Jun;35(3 Suppl 3):S13-21. Review. PubMed PMID: 18538174.
35: Horwitz SB. Introduction. The novel microtubule inhibitor vinflunine.
Semin Oncol. 2008 Jun;35(3 Suppl 3):S1-2. PubMed PMID: 18538173.
36: Calabrò F, Sternberg CN. The evolving role of chemotherapy in
advanced urothelial cancer. Curr Opin Support Palliat Care. 2007
Oct;1(3):180-6. Review. PubMed PMID: 18685360.
37: Lei XS, Yu XD, Yin L, Liu ZH, Tang PC. Synthesis and biological
evaluation of C-12' substituted vinflunine derivatives. Bioorg Med Chem
Lett. 2008 Aug 15;18(16):4602-5. Epub 2008 Jul 12. PubMed PMID:
18653334.
38: Honoré S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P,
Civiletti K, Kruczynski A, Braguer D. Antiangiogenic vinflunine affects
EB1 localization and microtubule targeting to adhesion sites. Mol Cancer
Ther. 2008 Jul;7(7):2080-9. PubMed PMID: 18645018.
39: Overmoyer B. Options for the treatment of patients with taxane-refractory
metastatic breast cancer. Clin Breast Cancer. 2008 Mar;8 Suppl 2:S61-70.
Review. PubMed PMID: 18637401.
40: Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer:
status of first-line chemotherapy and the search for active agents in
the second-line setting. Cancer. 2008 Sep 15;113(6):1284-93. Review.
PubMed PMID: 18629841.
41: Swain SM, Arezzo JC. Neuropathy associated with microtubule
inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol.
2008 Jun;6(6):455-67. Review. PubMed PMID: 18567992.
42: Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of
anthracycline- and taxane-refractory metastatic breast cancer. Semin
Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. Review. PubMed PMID:
18410797.
43: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098.
44: Yun-San Yip A, Yuen-Yuen Ong E, Chow LW. Vinflunine: clinical
perspectives of an emerging anticancer agent. Expert Opin Investig
Drugs. 2008 Apr;17(4):583-91. Review. PubMed PMID: 18363522.
45: Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new
microtubule inhibitor agent. Clin Cancer Res. 2008 Mar 15;14(6):1625-32.
Review. PubMed PMID: 18347163.
46: Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin
Cancer Res. 2008 Mar 15;14(6):1610-7. Review. PubMed PMID: 18347161.
47: Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV)
non-small cell lung cancer: more treatment options; more things to
consider. Conclusion. Oncologist. 2008;13 Suppl 1:37-46. Review. PubMed
PMID: 18263773.
48: Simoens C, Lardon F, Pauwels B, De Pooter CM, Lambrechts HA, Pattyn
GG, Breillout F, Vermorken JB. Comparative study of the radiosensitizing
and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC
Cancer. 2008 Feb 29;8:65. PubMed PMID: 18312675; PubMed Central PMCID:
PMC2311317.
49: Conte P, Guarneri V, Bengala C. Evolving nonendocrine therapeutic
options for metastatic breast cancer: how adjuvant chemotherapy
influences treatment. Clin Breast Cancer. 2007 Dec;7(11):841-9. Review.
PubMed PMID: 18269773.
50: Ploner F. [NSCLC: update on second line therapy following ASCO
2007]. Wien Med Wochenschr. 2007;157(21-22):540-4. Review. German.
PubMed PMID: 18157591.
51: Aggarwal A, Kruczynski A, Frankfurter A, Correia JJ, Lobert S.
Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to
vinflunine. Invest New Drugs. 2008 Aug;26(4):319-30. Epub 2007 Dec 11.
PubMed PMID: 18071633.
52: Makarov AA, Tsvetkov PO, Villard C, Esquieu D, Pourroy B, Fahy J,
Braguer D, Peyrot V, Lafitte D. Vinflunine, a novel microtubule
inhibitor, suppresses calmodulin interaction with the
microtubule-associated protein STOP. Biochemistry. 2007 Dec
25;46(51):14899-906. Epub 2007 Dec 4. PubMed PMID: 18052208.
53: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PubMed PMID: 18040531.
54: Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H,
Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P. Phase II study of
vinflunine in malignant pleural mesothelioma. J Clin Oncol. 2007 Oct
20;25(30):4751-6. PubMed PMID: 17947722.
55: Simoens C, Pauwels B, Vermorken JB, Pattyn GG, Lambrechts HA,
Breillout F, Lardon F. Further mechanistic unravelling of the influence
of the cell cycle effects on the radiosensitising mechanism of
vinflunine, in vitro. Cancer Chemother Pharmacol. 2008 Jul;62(2):183-93.
Epub 2007 Sep 27. PubMed PMID: 17899084.
56: Iaffaioli RV, Milano A, Caponigro F. Therapy of metastatic bladder
carcinoma. Ann Oncol. 2007 Jun;18 Suppl 6:vi153-6. Review. PubMed PMID:
17591811.
57: De Santis M, Bachner M. New developments in first- and second-line
chemotherapy for transitional cell, squamous cell and adenocarcinoma of
the bladder. Curr Opin Urol. 2007 Sep;17(5):363-8. Review. PubMed PMID:
17762632.
58: Walker K. American Society of Clinical Oncology--43rd annual
meeting. Research into therapeutics: Part 2. IDrugs. 2007
Aug;10(8):517-9. PubMed PMID: 17665321.
59: Olver IN, Byrne MJ, Walpole E, Vorobiof D, Jacobs C, Maart K, Hewitt
S, McAdam G, Pouget JC, Pinel MC. Phase II study of IV vinflunine in
patients with chemotherapy naive metastatic malignant melanoma. Eur J
Cancer. 2007 Aug;43(12):1829-32. Epub 2007 Jul 13. PubMed PMID:
17631996.
60: Zorza G, Van Heugen JC, De Graeve J, Puozzo C. Development of a
sensitive liquid chromatography method coupled with a tandem mass
spectrometric detection for the clinical analysis of vinflunine and
4-O-deacetyl vinflunine in blood, urine and faeces. J Chromatogr B
Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):294-302. Epub 2007
Mar 31. PubMed PMID: 17416213.
61: Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, Bunn
PA Jr, Varella-Garcia M, Hirsch FR. Unusual chemosensitivity of advanced
bronchioalveolar carcinoma after gefitinib response and progression: a
case report. J Thorac Oncol. 2007 Jan;2(1):91-2. PubMed PMID: 17410018.
62: Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable
bladder cancer. Semin Oncol. 2007 Apr;34(2):135-44. Review. PubMed PMID:
17382797.
63: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2007 Jan-Feb;29(1):53-71. PubMed PMID:
17344945.
64: Zhao XP, Zhong J, Liu XQ, Wang GJ. CYP3A4 mediated in vitro
metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin.
2007 Jan;28(1):118-24. PubMed PMID: 17184591.
65: Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G,
Ferlini C, Braguer D. Bcl-2 down-regulation and tubulin subtype
composition are involved in resistance of ovarian cancer cells to
vinflunine. Mol Cancer Ther. 2006 Nov;5(11):2824-33. PubMed PMID:
17121929.
66: Campone M, Cortes-Funes H, Vorobiof D, Martin M, Slabber CF,
Ciruelos E, Bourbouloux E, Mendiola C, Delgado FM, Colin C, Aslanis V,
Fumoleau P. Vinflunine: a new active drug for second-line treatment of
advanced breast cancer. Results of a phase II and pharmacokinetic study
in patients progressing after first-line anthracycline/taxane-based
chemotherapy. Br J Cancer. 2006 Nov 6;95(9):1161-6. Epub 2006 Oct 10.
PubMed PMID: 17031408; PubMed Central PMCID: PMC2360552.
67: Perabo FG, Müller SC. New agents for treatment of advanced
transitional cell carcinoma. Ann Oncol. 2007 May;18(5):835-43. Epub 2006
Oct 3. Review. PubMed PMID: 17018703.
68: Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C,
Giavazzi R, Hill BT, Taraboletti G. Anti-angiogenic, vascular-disrupting
and anti-metastatic activities of vinflunine, the latest vinca alkaloid
in clinical development. Eur J Cancer. 2006 Nov;42(16):2821-32. Epub
2006 Sep 14. PubMed PMID: 16973349.
69: Zhao XP, Liu XQ, Wang YS, Wang H, Wang GJ. Pharmacokinetics, tissue
distribution and excretion of vinflunine. Eur J Drug Metab Pharmacokinet.
2006 Apr-Jun;31(2):59-64. PubMed PMID: 16898072.
70: Roy V, Perez EA. New therapies in the treatment of breast cancer.
Semin Oncol. 2006 Jun;33(3 Suppl 9):S3-8. Review. PubMed PMID: 16797375.
71: Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M,
Kosmidis P, Huat TE, Pinel MC, Colin C, Douillard JY. Vinflunine -- an
active chemotherapy for treatment of advanced non-small-cell lung cancer
previously treated with a platinum-based regimen: results of a phase II
study. Br J Cancer. 2006 May 22;94(10):1383-8. PubMed PMID: 16641911;
PubMed Central PMCID: PMC2361262.
72: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2006 Mar;28(2):121-42. PubMed PMID: 16636723.
73: Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J,
Rolland F, Delgado FM, Longerey B, James N. A phase II study of
vinflunine in bladder cancer patients progressing after first-line
platinum-containing regimen. Br J Cancer. 2006 May 22;94(10):1395-401.
PubMed PMID: 16622447; PubMed Central PMCID: PMC2361290.
74: Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding
agents. Pathol Biol (Paris). 2006 Mar;54(2):72-84. Review. PubMed PMID:
16545633.
75: Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynski A,
Briand C, Braguer D. Antiangiogenic concentrations of vinflunine
increase the interphase microtubule dynamics and decrease the motility
of endothelial cells. Cancer Res. 2006 Mar 15;66(6):3256-63. PubMed
PMID: 16540678.
76: Goldstein D, Ackland SP, Bell DR, Olver IN, Davis ID, Rosenthal MA,
Toner GC, Pinel MC, Byrne M. Phase II study of vinflunine in patients
with metastatic renal cell carcinoma. Invest New Drugs. 2006
Sep;24(5):429-34. PubMed PMID: 16528478.
77: Zhao X, Liu X, Wang Y, Zhong J, Chen Y, Wang G. Determination of
vinflunine in rat plasma by liquid chromatography-electrospray
ionization mass spectrometry for a pharmacokinetic study. J Pharm Biomed
Anal. 2006 Jun 7;41(3):906-11. Epub 2006 Feb 3. PubMed PMID: 16460899.
78: Reddy K, D'Orazio A. Highlights from the International Conference on
Molecular Targets and Cancer Therapeutics: Discovery, Biology, And
Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The
European Cancer Conference, Paris, France, October 30-November 3, 2005.
Clin Genitourin Cancer. 2005 Dec;4(3):156-9. PubMed PMID: 16425983.
79: Jacoulet P. [Mesothelioma: advances in chemotherapy]. Rev Mal Respir.
2005 Dec;22(6 Pt 2):8S49-54. Review. French. PubMed PMID: 16340836.
80: Simoens C, Vermorken JB, Korst AE, Pauwels B, De Pooter CM, Pattyn
GG, Lambrechts HA, Breillout F, Lardon F. Cell cycle effects of
vinflunine, the most recent promising Vinca alkaloid, and its
interaction with radiation, in vitro. Cancer Chemother Pharmacol. 2006
Aug;58(2):210-8. Epub 2005 Nov 30. PubMed PMID: 16317558.
81: Erjala K, Raitanen M, Kulmala J, Grénman R. Head and neck carcinoma
cell lines are sensitive to vinflunine in vitro. Anticancer Res. 2005
Nov-Dec;25(6B):4363-7. PubMed PMID: 16309241.
82: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2005 Oct;27(8):569-612. PubMed PMID: 16273137.
83: Rombout F, Aarons L, Karlsson M, Man A, Mentré F, Nygren P, Racine
A, Schaefer H, Steimer JL, Troconiz I, van Peer A; COST B15 Experts.
Modelling and simulation in the development and use of anti-cancer
agents: an underused tool? J Pharmacokinet Pharmacodyn. 2004
Dec;31(6):419-40. Review. PubMed PMID: 16222783.
84: Johnson P, Geldart T, Fumoleau P, Pinel MC, Nguyen L, Judson I.
Phase I study of vinflunine administered as a 10-minute infusion on days
1 and 8 every 3 weeks. Invest New Drugs. 2006 May;24(3):223-31. PubMed
PMID: 16211365.
85: Bennouna J, Campone M, Delord JP, Pinel MC. Vinflunine: a novel
antitubulin agent in solid malignancies. Expert Opin Investig Drugs.
2005 Oct;14(10):1259-67. Review. PubMed PMID: 16185168.
86: Tillequin F, Koch M. [Acronycine revisited: development of benzo[b]acronycine
antitumor agents]. Ann Pharm Fr. 2005 Jan;63(1):35-43. Review. French.
PubMed PMID: 15803099.
87: Jacquesy JC, Jouannetaud MP. [Vinflunine: a new anti-cancer
fluorinated agent derived from Vinca-alkaloids]. Ann Pharm Fr. 2005
Jan;63(1):28-34. Review. French. PubMed PMID: 15803098.
88: Shnyder SD. Vinflunine. IDrugs. 2004 Sep;7(9):851-9. Review. PubMed
PMID: 15470603.
89: Pourroy B, Carré M, Honoré S, Bourgarel-Rey V, Kruczynski A, Briand
C, Braguer D. Low concentrations of vinflunine induce apoptosis in human
SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a
mitochondrial pathway. Mol Pharmacol. 2004 Sep;66(3):580-91. PubMed
PMID: 15322250.
90: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2004 Jun;26(5):357-91. PubMed PMID: 15319815.
91: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID: 15148527.
92: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review. PubMed PMID:
14988742.
93: Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA, Bibby MC.
Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil
in a transplantable murine adenocarcinoma model. Anticancer Res. 2003
Nov-Dec;23(6C):4815-20. PubMed PMID: 14981930.
94: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID: 14685303.
95: Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and
other newer agents in urothelial and kidney cancers. Crit Rev Oncol
Hematol. 2003 Jun 27;46 Suppl:S105-15. Review. PubMed PMID: 12850531.
96: Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine,
vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther.
2003 May;2(5):427-36. PubMed PMID: 12748304.
97: Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and
modified vinca alkaloids. Curr Med Chem Anticancer Agents. 2002
Jan;2(1):55-70. Review. PubMed PMID: 12678751.
98: Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM,
Puozzo C, Marty M. Phase I and pharmacokinetic study of the new vinca
alkaloid vinflunine administered as a 10-min infusion every 3 weeks in
patients with advanced solid tumours. Ann Oncol. 2003 Apr;14(4):630-7.
PubMed PMID: 12649112.
99: Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of
chemotherapy-induced myelosuppression with parameter consistency across
drugs. J Clin Oncol. 2002 Dec 15;20(24):4713-21. PubMed PMID: 12488418.
100: Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M. Higher
antitumor activity of vinflunine than vinorelbine against an orthotopic
murine model of transitional cell carcinoma of the bladder. Urol Oncol.
2002 Jul-Aug;7(4):159-66. PubMed PMID: 12474532.
101: Barthe L, Ribet JP, Pélissou M, Degude MJ, Fahy J, Duflos A.
Optimization of the separation of Vinca alkaloids by nonaqueous
capillary electrophoresis. J Chromatogr A. 2002 Aug 30;968(1-2):241-50.
PubMed PMID: 12236508.
102: Fabre C, Czaplicki J, Wright M, Hill B, Barret JM, Fahy J, Milon A.
Differential binding to the alpha/beta-tubulin dimer of vinorelbine and
vinflunine revealed by nuclear magnetic resonance analyses. Biochem
Pharmacol. 2002 Aug 15;64(4):733-40. PubMed PMID: 12167492.
103: Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT.
Characterization of cell death induced by vinflunine, the most recent
Vinca alkaloid in clinical development. Br J Cancer. 2002 Jan
7;86(1):143-50. PubMed PMID: 11857026; PubMed Central PMCID: PMC2746541.
104: Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in
clinical development. A review of its preclinical anticancer properties.
Crit Rev Oncol Hematol. 2001 Nov;40(2):159-73. Review. PubMed PMID:
11682323.
105: Etiévant C, Kruczynski A, Barret JM, Tait AS, Kavallaris M, Hill
BT. Markedly diminished drug resistance-inducing properties of
vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to
vinorelbine, identified in murine and human tumour cells in vivo and in
vitro. Cancer Chemother Pharmacol. 2001 Jul;48(1):62-70. PubMed PMID:
11488526.
106: Hill BT. Vinflunine, a second generation novel Vinca Alkaloid with
a distinctive pharmacological profile, now in clinical development and
prospects for future mitotic blockers. Curr Pharm Des. 2001
Sep;7(13):1199-212. Review. PubMed PMID: 11472262.
107: Fahy J. Modifications in the "upper" velbenamine part of the Vinca
alkaloids have major implications for tubulin interacting activities.
Curr Pharm Des. 2001 Sep;7(13):1181-97. Review. PubMed PMID: 11472261.
108: Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of
mitotic block and inhibition of cell proliferation by the semisynthetic
Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol
Pharmacol. 2001 Jul;60(1):225-32. PubMed PMID: 11408618.
109: Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine
in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001
Jan;84(2):290-5. PubMed PMID: 11161390; PubMed Central PMCID:
PMC2363703.
110: Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel
actions of the antitumor drugs vinflunine and vinorelbine on
microtubules. Cancer Res. 2000 Sep 15;60(18):5045-51. PubMed PMID:
11016627.
111: Lobert S, Fahy J, Hill BT, Duflos A, Etievant C, Correia JJ. Vinca
alkaloid-induced tubulin spiral formation correlates with cytotoxicity
in the leukemic L1210 cell line. Biochemistry. 2000 Oct
3;39(39):12053-62. PubMed PMID: 11009620.
112: von Angerer E. Tubulin as a target for anticancer drugs. Curr Opin
Drug Discov Devel. 2000 Sep;3(5):575-84. PubMed PMID: 19649885.
113: Lobert S, Correia JJ. Energetics of vinca alkaloid interactions
with tubulin. Methods Enzymol. 2000;323:77-103. PubMed PMID: 10944748.
114: Jean-Decoster C, Brichese L, Barret JM, Tollon Y, Kruczynski A,
Hill BT, Wright M. Vinflunine, a new vinca alkaloid: cytotoxicity,
cellular accumulation and action on the interphasic and mitotic
microtubule cytoskeleton of PtK2 cells. Anticancer Drugs. 1999
Jul;10(6):537-43. PubMed PMID: 10885901.
115: Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of
vinflunine, a novel fluorinated vinca alkaloid, in combination with
other anticancer drugs. Cancer Chemother Pharmacol. 2000;45(6):471-6.
PubMed PMID: 10854134.
116: Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A.
Superior in vivo experimental antitumour activity of vinflunine,
relative to vinorelbine, in a panel of human tumour xenografts. Eur J
Cancer. 1999 Mar;35(3):512-20. PubMed PMID: 10448309.
117: Etievant C, Barret JM, Kruczynski A, Perrin D, Hill BT. Vinflunine
(20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid,
which participates in P-glycoprotein (Pgp)-mediated multidrug resistance
in vivo and in vitro. Invest New Drugs. 1998;16(1):3-17. PubMed PMID:
9740539.
118: Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of
thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin
self-association by sedimentation velocity. Mol Pharmacol. 1998
May;53(5):908-15. PubMed PMID: 9584218.
119: Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT.
Preclinical in vivo antitumor activity of vinflunine, a novel
fluorinated Vinca alkaloid. Cancer Chemother Pharmacol.
1998;41(6):437-47. PubMed PMID: 9554586.
120: Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT.
Antimitotic and tubulin-interacting properties of vinflunine, a novel
fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48.
PubMed PMID: 9515574.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
